Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma

Lenvatinib (LEN) is the standard treatment for hepatocellular carcinoma (HCC). In clinical practice, gastrointestinal (GI) symptoms such as fatigue and loss of appetite often lead to dose reduction or treatment discontinuation. This study aimed to identify the predictors of patients who will experie...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of oncology pharmacy practice 2024-09, p.10781552241281900
Hauptverfasser:	Kimura, Michio, Yamada, Shiori, Go, Makiko, Yasuda, Satoshi, Toyoda, Hidenori, Usami, Eiseki
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!